Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	16,004	15,846	14,925	15,878	16,659	16,887
Revenue Growth (YoY)	7.22%	6.17%	-6.00%	-4.69%	-1.35%	-7.57%
Cost of Revenue	8,170	8,200	7,952	8,284	8,933	9,351
Gross Profit	7,834	7,646	6,973	7,594	7,726	7,536
Selling, General & Admin	3,542	3,498	3,445	3,528	3,671	3,806
Research & Development	962	953	838	967	997	1,010
Other Operating Expenses	3,115	2,762	4,887	1,384	6,629	3,164
Operating Expenses	7,619	7,213	9,170	5,879	11,297	7,980
Operating Income	215	433	-2,197	1,715	-3,571	-444
Interest Expense / Income	1,047	1,057	966	1,058	834	822
Other Expense / Income	-300	-58	-74	29	-247	11
Pretax Income	-532	-566	-3,089	628	-4,158	-1,277
Income Tax	-39	-7	-643	211	-168	-278
Net Income	-493	-559	-2,446	417	-3,990	-999
Shares Outstanding (Basic)	1,123	1,119	1,110	1,102	1,095	1,091
Shares Outstanding (Diluted)	1,123	1,119	1,110	1,107	1,095	1,091
Shares Change	0.72%	0.81%	0.27%	1.10%	0.37%	6.86%
EPS (Basic)	-0.44	-0.50	-2.20	0.38	-3.64	-0.91
EPS (Diluted)	-0.44	-0.50	-2.20	0.38	-3.64	-0.91
Free Cash Flow	878	842	1,042	236	638	223
Free Cash Flow Per Share	0.78	0.75	0.94	0.21	0.58	0.20
Gross Margin	48.95%	48.25%	46.72%	47.83%	46.38%	44.63%
Operating Margin	1.34%	2.73%	-14.72%	10.80%	-21.44%	-2.63%
Profit Margin	-3.08%	-3.53%	-16.39%	2.63%	-23.95%	-5.92%
Free Cash Flow Margin	5.49%	5.31%	6.98%	1.49%	3.83%	1.32%
Effective Tax Rate	-	-	-	33.60%	-	-
EBITDA	1,636	1,644	-815	3,016	-1,767	1,267
EBITDA Margin	10.22%	10.37%	-5.46%	18.99%	-10.61%	7.50%
Depreciation & Amortization	1,121	1,153	1,308	1,330	1,557	1,722
EBIT	515	491	-2,123	1,686	-3,324	-455
EBIT Margin	3.22%	3.10%	-14.22%	10.62%	-19.95%	-2.69%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).